Daniel S.W. Tan
Agency for Science, Technology and Research · 552 works · 18,758 citations · h-index 56
Top works
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
- Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
- The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- Coffee consumption and risk of type 2 diabetes mellitus
- Non-small-cell lung cancer
- Genomic landscape of lung adenocarcinoma in East Asians
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR -Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency
- Cost-Effectiveness of Screening and Vaccinating Asian and Pacific Islander Adults for Hepatitis B
- Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
- Biomarker-Driven Early Clinical Trials in Oncology